Inflammation as a Therapeutic Target in Heart Failure with Preserved Ejection Fraction

Zhen Hui Peh, Adel Dihoum, Dana Hutton, J. Simon C. Arthur, Graham Rena, Faisel Khan, Chim C. Lang, Ify R. Mordi (Lead / Corresponding author)

Research output: Contribution to journalReview articlepeer-review

2 Citations (Scopus)
41 Downloads (Pure)


Heart failure with preserved ejection fraction (HFpEF) accounts for around half of all cases of heart failure and may become the dominant type of heart failure in the near future. Unlike HF with reduced ejection fraction there are few evidence-based treatment strategies available. There is a significant unmet need for new strategies to improve clinical outcomes in HFpEF patients. Inflammation is widely thought to play a key role in HFpEF pathophysiology and may represent a viable treatment target. In this review focusing predominantly on clinical studies, we will summarise the role of inflammation in HFpEF and discuss potential therapeutic strategies targeting inflammation.
Original languageEnglish
Article number1125687
Number of pages14
JournalFrontiers in Cardiovascular Medicine
Publication statusPublished - 29 Jun 2023


  • inflammation
  • heart failure
  • HFpEF
  • interleukins
  • cardiometabolic

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Inflammation as a Therapeutic Target in Heart Failure with Preserved Ejection Fraction'. Together they form a unique fingerprint.

Cite this